Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Can-Fite BioPharma ( (CANF) ) has provided an announcement.
Can-Fite BioPharma announced that its liver-protective drug, Namodenoson, will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. Namodenoson is currently in a Phase 3 trial for advanced liver cancer and has shown potential not only in treating cancer but also in protecting the liver. This dual action sets Namodenoson apart from other treatments that often come with liver toxicity. The drug’s unique mechanism is mediated through the adiponectin protein, indicating its broad protective properties. This recognition and ongoing trials could enhance Can-Fite’s positioning in the oncology market, potentially offering a safer treatment option for liver cancer patients.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company that focuses on developing proprietary small molecule drugs for oncology and inflammatory diseases. The company aims to address multi-billion dollar markets with its lead drug candidates targeting liver diseases, cancer, and inflammation-related conditions.
YTD Price Performance: -28.18%
Average Trading Volume: 446,420
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.56M
See more insights into CANF stock on TipRanks’ Stock Analysis page.
